FindTrial
Sign In

SNB-101

DRUG2 trials

Sponsors

SN BioScience

Conditions

Breast CancerColorectal CancerGastric CancerHead and Neck CancerOvarian CancerPancreas CancerPatient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)Small-cell Lung Cancer

Phase 1

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
CompletedNCT04640480
SN BioScienceBreast Cancer, Colorectal Cancer, Gastric Cancer +4
Start: 2020-10-21End: 2026-01-05Updated: 2026-01-27
SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
RecruitingNCT07391813
SN BioSciencePatient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)
Start: 2026-03-01End: 2028-12-01Target: 55Updated: 2026-03-09

Related Papers

Model-based prediction of nanoparticle and dissolved form ratios using total concentration data: a case study of SNB-101
Frontiers in Pharmacology2025-08-21